Cargando…

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer

Molecular factors that drive metastasis in premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), early breast cancer (EBC) are largely unknown. To identify markers/signatures contributing to metastasis, we analyzed molecular changes i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Hua, Kumbrink, Jörg, Mayr, Doris, Seiler, Alina, Hagemann, Friederike, Degenhardt, Tom, Sagebiel, Sabine, Würstlein, Rachel, Kates, Ronald, Harbeck, Nadia, Eggersmann, Tanja K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468490/ https://www.ncbi.nlm.nih.gov/pubmed/34575612 http://dx.doi.org/10.3390/jpm11090835

Ejemplares similares

The association of immunosurveillance and distant metastases in colorectal cancer
por: Jacob, Sven, et al.
Publicado: (2021)

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
por: Bardia, Aditya, et al.
Publicado: (2021)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer
por: Tripathy, Debu, et al.
Publicado: (2022)

HER2 gene status in primary breast cancers and matched distant metastases
por: Tapia, Coya, et al.
Publicado: (2007)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
por: Almstedt, Katrin, et al.
Publicado: (2023)

Distant metastases
Publicado: (1998)

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
por: Gong, Gyungyub, et al.
Publicado: (2017)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Combining TMEM Doorway Score and Mena(Calc) Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients
por: Ye, Xianjun, et al.
Publicado: (2022)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers
por: Schindler, Florian, et al.
Publicado: (2023)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases
por: Srikantia, Nirmala, et al.
Publicado: (2009)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

1592P Willingness to vaccinate and side effects of COVID-19 vaccination in patients with breast cancer and gynecological malignancies
por: Forster, M., et al.
Publicado: (2021)

Receptor conversion in distant breast cancer metastases
por: Hoefnagel, Laurien DC, et al.
Publicado: (2010)

Supportivtherapie bei Brustkrebs: Die Einführung oraler Therapien und neuer Substanz erfordern ein adäquates Nebenwirkungsmanagement
por: Stefan, Alexandra, et al.
Publicado: (2023)

Supportivtherapie bei Brustkrebs: Einführung oraler Therapien und neuer Substanzen erfordert ein adäquates Nebenwirkungsmanagement
por: Stefan, Alexandra, et al.
Publicado: (2023)

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
por: Cardoso, Fatima, et al.
Publicado: (2023)

Multiple disseminated keratoacanthoma-like nodules: a rare form of distant metastases to the skin
por: Jankowska-Konsur, Alina, et al.
Publicado: (2018)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Promoter hypermethylation profiling of distant breast cancer metastases
por: Schrijver, Willemijne A. M. E., et al.
Publicado: (2015)

Hurthle Cells Adenoma With Distant Metastases Refractory to Radioiodine
por: Rosario, Pedro Weslley, et al.
Publicado: (2021)

Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy
por: Jia, Zhifeng, et al.
Publicado: (2023)

Trust based attachment
por: Kates-Harbeck, Julian, et al.
Publicado: (2023)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Feminizing Adrenocortical Carcinoma with Distant Metastases: Can Surgery be Considered?
por: Fancellu, Alessandro, et al.
Publicado: (2014)

Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis
por: Chen, Ming-Yuan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3hatkemo5njdk858qrc65uv300